PFS
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Pasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Maximilian Hochmair, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W Neal, Terufumi Kato, Yi-Long Wu, Danny Nguyen, Junjing Lin, Jianchang Lin, Florin Vranceanu, Annette Szumski, Huamao M Lin, Robert J Fram, Tony S K Mok
J Clin Oncol 43(13) 1553-1563
PURPOSE: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2, ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of EGFR ex20ins+ advanced/metastatic NSCLC. METHODS: Patients with treatment-naive EGFR ex20ins+ locally advanced/metastatic NSCLC were randomly assigned 1:1 to mobocertinib 160 mg once daily or pemetrexed plus cisplatin or carboplatin every 3 weeks for four cycles followed by maintenance pemetrexed. The primary end point was progression-free survival (PFS) by blinded independent central review (BICR), with planned interim analysis (IA) after approximately 70% of 227 expected PFS events. RESULTS: A total of 354 patients were randomly assigned (mobocertinib: n = 179; chemotherapy: n = 175). Baseline characteristics were balanced between arms. At IA (cutoff: April 4, 2023), the median PFS per BICR was 9.6 months in each treatment arm (hazard ratio [HR], 1.04 [95% CI, 0.77 to 1.39]; P = .803). The primary end point crossed the prespecified futility boundary (HR > 1). The confirmed objective response rate (95% CI) per BICR was 32% (26 to 40) with mobocertinib versus 30% (24 to 38) with chemotherapy; the median duration of response was 12.0 versus 8.4 months. Quality-of-life assessments indicated clinically meaningful delays in time to deterioration of lung cancer symptoms, cognitive function, and constipation with mobocertinib versus chemotherapy. Grade ≥3 adverse events in >5% of patients (mobocertinib, chemotherapy) were diarrhea (20%, 1%), anemia (6%, 10%), increased lipase (6%, 0%), and decreased neutrophil count (1%, 7%). CONCLUSION: The EXCLAIM-2 trial did not meet its primary end point. The efficacy of mobocertinib was not superior to platinum-based chemotherapy for first-line treatment of patients with EGFR ex20ins+ advanced/metastatic NSCLC.
2 个 Figure · 4 个 KM 面板
FIG 2. Efficacy of first-line mobocertinib versus platinum-based chemotherapy in patients with EGFR ex20ins+ NSCLC. (A) Kaplan-Meier–estimated PFS by BICR assessment in the ITT population. (B) Forest plot of HRs for BICR-assessed PFS across patient subgroups. HRs are based on an unstratified Cox proportional hazards regression model. (C) DoR in confirmed responders. (D) OS in the ITT population. a <1 HR for treatment indicates better prevention of progression or death in the mobocertinib arm compared with the chemotherapy arm. BICR, blinded independent central review; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; EGFR ex20ins, epidermal growth factor receptor exon 20 insertion; HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; NSCLC, non–small cell lung cancer; OS, overalll survival; PFS, progression-free survival.
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel C
Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel D
Panel D 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. TTD in patient-reported lung cancer symptoms. TTD in the EORTC QLQ-LC13 composite lung cancer symptom score (cough, dyspnea, and chest pain). A clinically meaningful change was defined as an 11.1-point (for dyspnea) or 33.3-point (for cough or chest pain) deterioration for the EORTC QLQ-LC13 composite score scale. EORTC, European Organization for Research and Treatment of Cancer; HR, hazard ratio; NE, not estimable; QLQ-LC13, quality-of-life questionnaire-lung cancer 13; TTD, time to deterioration.
FIG 3. · Panel Deterioration_Free_of_patients_
Panel Deterioration_Free_of_patients_ 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。